Health News
Health News

In-Ear EEG Wearable NeuroBuds Receives CE Mark for Extended Ambulatory Monitoring

By Marcus Reid ·

CE Mark Opens European Market for Home-Based EEG Monitoring

Cebreo Medical recently secured CE marking for NeuroBuds, an in-ear EEG device designed for long-duration ambulatory monitoring. This clearance allows the technology to enter the European market, marking a shift toward home-based care. Unlike traditional EEG systems that require a technician to apply an electrode cap, NeuroBuds operates without direct assistance, even in the patient’s own home. Its hearing-aid-like form was chosen to reduce stigma and discomfort associated with long-term brain monitoring. The device can record for up to three months, capturing data across multiple days and nights in the patient’s daily environment.

Discreet, Non-Invasive Monitoring Reduces Costs and Improves Decisions

„With NeuroBuds, we can offer a discreet and non-invasive solution that enables long-term EEG monitoring, without assistance, for weeks, in patients’ own homes. The product has the potential to significantly reduce the costs of long-term EEG monitoring and to strengthen therapeutic decisions compared with conventional brain monitoring methods,” says Rasmus Madsen, PhD, CEO of Cebreo Medical, in an official statement.

Applications in Sleep Medicine, Epilepsy, and Neurophysiology

Extended ambulatory EEG monitoring has broad applications across sleep medicine, epilepsy, and other neurophysiological research areas. For patients with treatment-resistant epilepsy, therapeutic decisions rely on a precise, longitudinal picture of seizure frequency and treatment response. „For patients with drug-resistant epilepsy, the question is not whether they have seizures — it is how often they occur and whether a new treatment actually works. The number of seizures reported by patients is often insignificant, especially for subtle or nocturnal seizures that patients do not notice. An ambulatory in-ear EEG device that can operate for weeks in the patient’s daily life provides EEG data with the potential to objectively quantify seizure burden and, consequently, to more accurately assess treatment efficacy,” explains Sandor Beniczky, MD, PhD, professor in the department of clinical neurophysiology at Rigshospitalet and the Danish Epilepsy Center.

European Rollout and US Regulatory Path Forward

Following the CE marking, Cebreo Medical plans to expand commercial availability across multiple European research and clinical sites, while simultaneously pursuing US regulatory approval. This strategic move aims to solidify the technology’s presence in the European market, offering a modern and accessible alternative for diagnosing and monitoring complex neurological conditions.